{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:25:09Z","timestamp":1790796309640,"version":"4.1.0"},"reference-count":72,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Trends in Endocrinology & Metabolism"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1016\/j.tem.2011.09.001","type":"journal-article","created":{"date-parts":[[2011,10,17]],"date-time":"2011-10-17T02:14:24Z","timestamp":1318817664000},"page":"499-506","source":"Crossref","is-referenced-by-count":172,"title":["Diabetes in Cushing syndrome: basic and clinical aspects"],"prefix":"10.1016","volume":"22","author":[{"given":"Gherardo","family":"Mazziotti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"Gazzaruso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Giustina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tem.2011.09.001_bib0005","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1210\/jc.2010-1942","article-title":"Mortality and morbidity in Cushing's disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature","volume":"96","author":"Clayton","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2011.09.001_bib0010","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1365-2265.1994.tb02486.x","article-title":"Morbidity and mortality in Cushing's disease: an epidemiological approach","volume":"40","author":"Etxabe","year":"1994","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.tem.2011.09.001_bib0015","doi-asserted-by":"crossref","first-page":"6348","DOI":"10.1210\/jc.2003-032180","article-title":"Transsphenoidal microsurgery for Cushing's disease: initial outcomes and long-term results","volume":"89","author":"Hammer","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2011.09.001_bib0020","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1210\/jc.2006-2112","article-title":"Mortality in patients treated for Cushing's disease is increased, compared with patients treated for non-functioning pituitary macroadenomas","volume":"92","author":"Dekkers","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2011.09.001_bib0025","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1365-2362.2008.02067.x","article-title":"Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options?","volume":"39","author":"van Raalte","year":"2009","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.tem.2011.09.001_bib0030","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2183\/pjab.86.563","article-title":"Pancreatic \u03b2-cell signaling: toward better understanding of diabetes and its treatment","volume":"86","author":"Seino","year":"2010","journal-title":"Proc. Jpn. Acad. Ser."},{"key":"10.1016\/j.tem.2011.09.001_bib0035","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.1210\/jc.2010-0119","article-title":"Reduced glucose tolerance and insulin resistance induced by steroid treatment, relative physical inactivity, and high-calorie diet impairs the incretin effect in healthy subjects","volume":"95","author":"Hansen","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"Suppl. 1","key":"10.1016\/j.tem.2011.09.001_bib0040","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1159\/000314319","article-title":"Pathophysiology of diabetes mellitus in Cushing's Syndrome","volume":"92","author":"Pivonello","year":"2010","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.tem.2011.09.001_bib0045","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1385\/ENDO:29:1:81","article-title":"Adipocyte-derived hormones, cytokines, and mediators","volume":"29","author":"Rondinone","year":"2006","journal-title":"Endocrine"},{"key":"10.1016\/j.tem.2011.09.001_bib0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12020-011-9507-9","article-title":"Apelin, diabetes, and obesity","volume":"40","author":"Castan-Laurell","year":"2011","journal-title":"Endocrine"},{"key":"10.1016\/j.tem.2011.09.001_bib0055","doi-asserted-by":"crossref","first-page":"33873","DOI":"10.1074\/jbc.M504119200","article-title":"Glucocorticoids regulate transcription of the gene for phosphoenolpyruvate carboxykinase in the liver via an extended glucocorticoid regulatory unit","volume":"280","author":"Cassuto","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tem.2011.09.001_bib0060","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1172\/JCI41681","article-title":"LXR\u03b2 is required for glucocorticoid-induced hyperglycemia and hepatosteatosis in mice","volume":"121","author":"Patel","year":"2011","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tem.2011.09.001_bib0065","doi-asserted-by":"crossref","first-page":"469","DOI":"10.4158\/EP08331.RAR","article-title":"Glucocorticoid-induced hyperglycemia","volume":"15","author":"Clore","year":"2009","journal-title":"Endocr. Pract."},{"key":"10.1016\/j.tem.2011.09.001_bib0070","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1001\/archinte.1994.00420010131015","article-title":"Glucocorticoids and the risk for initiation of hypoglycemic therapy","volume":"154","author":"Gurwitz","year":"1994","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.tem.2011.09.001_bib0075","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1007\/s001250050847","article-title":"Risk and mechanism of dexamethasone-induced deterioration of glucose tolerance in non-diabetic first-degree relatives of NIDDM patients","volume":"40","author":"Henriksen","year":"1997","journal-title":"Diabetologia"},{"key":"10.1016\/j.tem.2011.09.001_bib0080","first-page":"E995","article-title":"Insulin resistance induced by hydrocortisone is increased in patients with abdominal obesity","volume":"291","author":"Darmon","year":"2006","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.tem.2011.09.001_bib0085","doi-asserted-by":"crossref","first-page":"358","DOI":"10.4158\/EP.12.4.358","article-title":"Prevalence and predictors of corticosteroid-related hyperglycemia in hospitalized patients","volume":"12","author":"Donihi","year":"2006","journal-title":"Endocr. Pract."},{"key":"10.1016\/j.tem.2011.09.001_bib0090","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1007\/s00125-011-2174-9","article-title":"Low-dose glucocorticoid treatment affects multiple aspects of intermediary metabolism in healthy humans: a randomised controlled trial","volume":"54","author":"van Raalte","year":"2011","journal-title":"Diabetologia"},{"key":"10.1016\/j.tem.2011.09.001_bib0095","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1507\/endocrj.43.645","article-title":"Carbohydrate and lipid metabolism in endogenous hypercortisolism: shared features with metabolic syndrome X and NIDDM","volume":"43","author":"Friedman","year":"1996","journal-title":"Endocr. J."},{"key":"10.1016\/j.tem.2011.09.001_bib0100","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1046\/j.1563-2571.2000.00106.x","article-title":"Prevalence of diabetes in acromegaly and Cushing syndrome","volume":"27","author":"Biering","year":"2000","journal-title":"Acta Med. Austriaca"},{"key":"10.1016\/j.tem.2011.09.001_bib0105","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/j.1365-2265.2004.02168.x","article-title":"High cardiovascular risk in patients with Cushing's syndrome according to 1999 WHO\/ISH guidelines","volume":"61","author":"Mancini","year":"2004","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.tem.2011.09.001_bib0110","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1210\/jc.2002-021518","article-title":"Gender-related differences in the presentation and course of Cushing's disease","volume":"88","author":"Pecori Giraldi","year":"2003","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2011.09.001_bib0115","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s12020-009-9260-5","article-title":"Adrenal incidentaloma, clinical, metabolic, follow-up aspects: single centre experience","volume":"37","author":"Comlekci","year":"2010","journal-title":"Endocrine"},{"key":"10.1016\/j.tem.2011.09.001_bib0120","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/j.1365-2265.2010.03928.x","article-title":"The size of adrenal incidentalomas correlates with insulin resistance. Is there a cause\u2013effect relationship?","volume":"74","author":"Muscogiuri","year":"2011","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.tem.2011.09.001_bib0125","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1530\/eje.1.01959","article-title":"Midnight serum cortisol as a marker of increased cardiovascular risk in patients with a clinically inapparent adrenal adenoma","volume":"153","author":"Terzolo","year":"2005","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.tem.2011.09.001_bib0130","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1365-2265.2010.03794.x","article-title":"Subclinical hypercortisolism: correlation between biochemical diagnostic criteria and clinical aspects","volume":"73","author":"Morelli","year":"2010","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.tem.2011.09.001_bib0135","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1210\/jc.2010-2722","article-title":"Diagnosis and treatment of subclinical hypercortisolism","volume":"96","author":"Chiodini","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2011.09.001_bib0140","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1210\/jc.2009-2453","article-title":"Is there value in routine screening for Cushing's syndrome in patients with diabetes?","volume":"95","author":"Mullan","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2011.09.001_bib0145","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.2337\/dc11-S062","article-title":"Diagnosis and classification of diabetes mellitus","volume":"34","author":"American Diabetes Association","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.tem.2011.09.001_bib0150","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1210\/jc.2010-2729","article-title":"Continuous monitoring of circadian glycemic patterns in patients receiving prednisolone for COPD","volume":"96","author":"Morton","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2011.09.001_bib0155","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.amjmed.2010.11.025","article-title":"Implications of using hemoglobin A1c for diagnosing diabetes mellitus","volume":"124","author":"Malkani","year":"2011","journal-title":"Am. J. Med."},{"key":"10.1016\/j.tem.2011.09.001_bib0160","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"key":"10.1016\/j.tem.2011.09.001_bib0165","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1093\/ndt\/gfn052","article-title":"New-onset diabetes after transplantation \u2013 should it be a factor in choosing an immunosuppressant regimen for kidney transplant recipients","volume":"23","author":"Chadban","year":"2008","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.tem.2011.09.001_bib0170","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.tem.2006.03.009","article-title":"Glucocorticoid-induced osteoporosis: an update","volume":"17","author":"Mazziotti","year":"2006","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.tem.2011.09.001_bib0175","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0168-8227(02)00104-3","article-title":"Repaglinide versus glibenclamide treatment of type 2 diabetes during Ramadan fasting","volume":"58","author":"Mafauzy","year":"2002","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.tem.2011.09.001_bib0180","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.bone.2009.06.006","article-title":"Vertebral fractures in males with type 2 diabetes treated with rosiglitazone","volume":"45","author":"Mancini","year":"2009","journal-title":"Bone"},{"key":"10.1016\/j.tem.2011.09.001_bib0185","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.amjmed.2010.02.028","article-title":"Drug-induced osteoporosis: mechanisms and clinical implications","volume":"123","author":"Mazziotti","year":"2010","journal-title":"Am. J. Med."},{"key":"10.1016\/j.tem.2011.09.001_bib0190","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1056\/NEJMoa073394","article-title":"Rosiglitazone evaluated for cardiovascular outcomes \u2013 an interim analysis","volume":"357","author":"Home","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tem.2011.09.001_bib0195","doi-asserted-by":"crossref","first-page":"412","DOI":"10.2337\/dc10-1677","article-title":"Glucagon-like peptide-1 receptor agonist treatment prevents glucocorticoid-induced glucose intolerance and islet-cell dysfunction in humans","volume":"34","author":"van Raalte","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.tem.2011.09.001_bib0200","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1185\/030079907X253870","article-title":"Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years","volume":"24","author":"Klonoff","year":"2008","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.tem.2011.09.001_bib0205","doi-asserted-by":"crossref","first-page":"5593","DOI":"10.1210\/jc.2003-030871","article-title":"Diagnosis and complications of Cushing's syndrome: a consensus statement","volume":"88","author":"Arnaldi","year":"2003","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2011.09.001_bib0210","first-page":"505","article-title":"Treatment of Cushing disease: overview and recent findings","volume":"21","author":"Mancini","year":"2010","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.tem.2011.09.001_bib0215","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1210\/jc.2004-0545","article-title":"Growth hormone and cardiovascular risk factors","volume":"90","author":"Gola","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2011.09.001_bib0220","doi-asserted-by":"crossref","first-page":"3954","DOI":"10.1210\/jc.2006-0524","article-title":"The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients","volume":"91","author":"Filipsson","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2011.09.001_bib0225","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1530\/EJE-10-0125","article-title":"Glucocorticoid replacement therapy and vertebral fractures in hypopituitary adult males with GH deficiency","volume":"163","author":"Mazziotti","year":"2010","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.tem.2011.09.001_bib0230","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1210\/jc.2007-2734","article-title":"Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement","volume":"93","author":"Biller","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2011.09.001_bib0235","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.clinthera.2008.05.021","article-title":"Safety profile and metabolic effects of 14 days of treatment with DIO-902: results of a phase IIa multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in patients with type 2 diabetes mellitus","volume":"30","author":"Schwartz","year":"2008","journal-title":"Clin. Ther."},{"key":"10.1016\/j.tem.2011.09.001_bib0240","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1210\/jc.2008-1533","article-title":"The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery","volume":"94","author":"Pivonello","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2011.09.001_bib0245","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.2337\/diacare.23.8.1154","article-title":"Bromocriptine: a novel approach to the treatment of type 2 diabetes","volume":"23","author":"Pijl","year":"2000","journal-title":"Diabetes Care"},{"key":"10.1016\/j.tem.2011.09.001_bib0250","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1210\/en.139.1.414","article-title":"Cell specific expression of the sst2 A and sst5 somatostatin receptors in the rat anterior pituitary","volume":"139","author":"Mezey","year":"1998","journal-title":"Endocrinology"},{"key":"10.1016\/j.tem.2011.09.001_bib0255","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1210\/jc.2008-2421","article-title":"Guidelines for acromegaly management: an update","volume":"94","author":"Melmed","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2011.09.001_bib0260","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1210\/endo-110-4-1147","article-title":"Glucocorticoids down-regulate somatostatin receptors on pituitary cells in culture","volume":"110","author":"Schonbrunn","year":"1982","journal-title":"Endocrinology"},{"key":"10.1016\/j.tem.2011.09.001_bib0265","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0168-8227(91)90052-F","article-title":"Low-dose octreotide is able to cause a maximal inhibition of the glycemic responses to a mixed meal in obese type 2 diabetic patients treated with insulin","volume":"14","author":"Giustina","year":"1991","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.tem.2011.09.001_bib0270","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1365-2265.2006.02452.x","article-title":"Effect of protracted treatment with rosiglitazone, a PPARgamma agonist, in patients with Cushing's disease","volume":"64","author":"Pecori-Giraldi","year":"2006","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.tem.2011.09.001_bib0275","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1530\/eje.0.1510173","article-title":"Effects of chronic administration of PPAR-gamma ligand rosiglitazone in Cushing's disease","volume":"151","author":"Ambrosi","year":"2004","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.tem.2011.09.001_bib0280","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1210\/jc.2004-1746","article-title":"Effect of pioglitazone on adrenocorticotropic hormone and cortisol secretion in Cushing's disease","volume":"90","author":"Suri","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2011.09.001_bib0285","doi-asserted-by":"crossref","first-page":"450","DOI":"10.4158\/EP.15.5.450","article-title":"American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons medical guidelines for the management of adrenal incidentalomas: executive summary of recommendations","volume":"15","author":"Zeiger","year":"2009","journal-title":"Endocr. Pract."},{"key":"10.1016\/j.tem.2011.09.001_bib0290","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1590\/S0004-27302007000800013","article-title":"Subclinical Cushing's syndrome","volume":"51","author":"Terzolo","year":"2007","journal-title":"Arq. Bras. Endocrinol. Metabol."},{"key":"10.1016\/j.tem.2011.09.001_bib0295","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1210\/jc.84.8.2664","article-title":"Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure","volume":"84","author":"Colao","year":"1999","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2011.09.001_bib0300","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1210\/jc.2009-0806","article-title":"Metabolic, cardiovascular, and cerebrovascular outcomes in growth hormone-deficient subjects with previous Cushing's disease or non-functioning pituitary adenoma","volume":"95","author":"Webb","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2011.09.001_bib0305","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00592-009-0112-9","article-title":"Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities","volume":"46","author":"Resmini","year":"2009","journal-title":"Acta Diabetol."},{"key":"10.1016\/j.tem.2011.09.001_bib0310","doi-asserted-by":"crossref","first-page":"4342","DOI":"10.1210\/jc.2009-1311","article-title":"Differential ligand-mediated pituitary somatostatin receptor subtype signaling: implications for corticotroph tumor therapy","volume":"94","author":"Ben-Shlomo","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2011.09.001_bib0315","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1159\/000314352","article-title":"Medical treatment of Cushing's disease: somatostatin analogues and pasireotide","volume":"92","author":"Pedroncelli","year":"2010","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.tem.2011.09.001_bib0320","doi-asserted-by":"crossref","first-page":"3790","DOI":"10.1210\/en.140.8.3790","article-title":"Colocalization of somatostatin receptor sst5 and insulin in rat pancreatic beta-cells","volume":"140","author":"Mitra","year":"1999","journal-title":"Endocrinology"},{"key":"10.1016\/j.tem.2011.09.001_bib0325","article-title":"Pasireotide (SOM230), a novel multi-receptor-targeted somatostatin analogue, is well tolerated when administered as a continuous 7 day subcutaneous infusion in healthy male volunteers","author":"Petersenn","year":"2011","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.tem.2011.09.001_bib0330","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1210\/jc.2008-1008","article-title":"Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial","volume":"94","author":"Boscaro","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2011.09.001_bib0335","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1055\/s-0030-1270523","article-title":"Transient efficacy of octreotide and pasireotide (SOM230) treatment in GIP-dependent Cushing's syndrome","volume":"43","author":"Preumont","year":"2011","journal-title":"Horm. Metab. Res."},{"key":"10.1016\/j.tem.2011.09.001_bib0340","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s11102-006-0410-y","article-title":"Growth hormone deficiency in the adult","volume":"9","author":"Doga","year":"2006","journal-title":"Pituitary"},{"key":"10.1016\/j.tem.2011.09.001_bib0345","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1210\/er.2007-0036","article-title":"Growth hormone, insulin-like growth factors, and the skeleton","volume":"29","author":"Giustina","year":"2008","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.tem.2011.09.001_bib0350","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1210\/jc.2008-2332","article-title":"Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies","volume":"94","author":"Mazziotti","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2011.09.001_bib0355","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1530\/EJE-10-0811","article-title":"Effects of high-dose octreotide LAR on glucose metabolism in patients with acromegaly inadequately controlled by conventional somatostatin analog therapy","volume":"164","author":"Mazziotti","year":"2011","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.tem.2011.09.001_bib0360","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1056\/NEJMc1000094","article-title":"Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease","volume":"362","author":"Feelders","year":"2010","journal-title":"N. Engl. J. Med."}],"container-title":["Trends in Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104327601100138X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104327601100138X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T15:44:57Z","timestamp":1713023097000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104327601100138X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":72,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S104327601100138X"],"URL":"https:\/\/doi.org\/10.1016\/j.tem.2011.09.001","relation":{},"ISSN":["1043-2760"],"issn-type":[{"value":"1043-2760","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}